NTX-253 Moves Toward Phase 2 Testing for Schizophrenia
Neurosterix has completed phase 1 trials of NTX-253, an oral M4 positive allosteric modulator being developed for schizophrenia. The initial trial produced encouraging data on tolerability and how the body processes the drug. The company is advancing the candidate into phase 2 testing.
Neurosterix has finished phase 1 testing of NTX-253, an oral M4 positive allosteric modulator intended for schizophrenia. The early-stage trial yielded encouraging findings on tolerability and pharmacokinetics, or how the body handles the drug. With those results, the company is moving the candidate into phase 2 testing. The update places NTX-253 within the broader effort to develop new schizophrenia treatments, though it remains an investigational compound and further clinical study is needed.
If phase 2 proceeds, people living with schizophrenia and their families may gain another potential treatment option to watch, though success is uncertain. Clinicians and researchers could see continued interest in M4-targeted oral approaches. For society, new options might eventually affect treatment discussions and access, but only if later trials confirm benefits and regulators approve the drug. The near-term impact is likely limited to the research community and future study participants.